ClinicalTrials.govpublic full text
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
clostridium difficile infection recurrence, c.diff, clostridium difficile, recurrence, bezlotoxumab, cdi, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 891531
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.